Trial Profile
A phase II multicenter study to assessed safety and tolerability of PARI Tobramycin 100 administered via an Investigational eFlow Nebulizer System in comparison to TOBI delivered via the PARI LC PLUS in patients suffering from cystic fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2015
Price :
$35
*
At a glance
- Drugs Tobramycin (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 12 Mar 2015 New trial record